China announced a ban on Tuesday on imports of genetic sequencers from U.S. medical equipment maker Illumina , just minutes after U.S. President Donald Trump's additional 10% tariff on Chinese goods took effect.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Illumina, Inc. (NASDAQ:ILMN ) AGBT Investor Session Conference February 25, 2025 11:00 AM ET Company Participants Salli Schwartz - Head of Investor Relations Jacob Thaysen - Chief Executive Officer Steve Barnard - Chief Technology Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Subbu Nambi - Guggenheim Securities Dan Brennan - TD Cowen Dan Arias - Stifel Puneet Souda - SVB Securities Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies LLC Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Kyle Mikson - Canaccord Genuity Salli Schwartz Welcome. Thank you for your patience while we got started.
Illumina Collaborates with Broad Clinical Labs to set the standard for scalable single-cell research and accelerate discovery in areas such as disease modeling and drug development.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Illumina (ILMN) and Alnylam Pharmaceuticals (ALNY). But which of these two stocks offers value investors a better bang for their buck right now?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
On Monday, for the second time in as many business days, Illumina (ILMN -5.47%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% lower, during a session when the S&P 500 (^GSPC 0.67%) landed in the black with a 0.7% increase.
Review Illumina's (ILMN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Illumina restored its profitability well: Free Cash Flow is reaching elevated levels. However, the placement of ILMN in China's unreliable entity list could have disruptive implications for its operations in the country. The maximum exposure is 7% of its sales, which is manageable.
Shares of Illumina (ILMN -8.97%) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m.
Illumina, Inc. ILMN reported better-than-expected results for its fourth quarter on Thursday.